↑: Increased with regard to normal levels; ↓: Decreased with regard to normal levels; CTL: Cytotoxic T lymphocyte; MDS: Myelodysplastic syndrome.

↑: Increased with regard to normal levels; ↓: Decreased with regard to normal levels; CTL: Cytotoxic T lymphocyte; MDS: Myelodysplastic syndrome.

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

Myelodysplastic syndrome (MDS) is a rare haematological cancer characterized by abnormal development and maturation (dysplasia) of immature blood cells in the bone marrow, resulting in varying ...

If you have MDS, a type of blood cancer called myelodysplastic syndrome, you’re part of a rare group of people with the diagnosis. But research is ongoing. Many clinical trials are seeking new ...

If you’ve just found out you have myelodysplastic syndrome (MDS), you’ll surely have lots of questions. You may never have heard of MDS before or known anyone who had it. You may feel a wide ...

Zilurgisertib fumarate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome.

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding ...

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.